Vistagen therapeutics.

Should You Buy or Sell Vistagen Therapeutics Stock? Get The Latest VTGN Stock Analysis, Price Target, Headlines, and Short Interest at MarketBeat.Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other ...Discover historical prices for VTGN stock on Yahoo Finance. View daily, weekly or monthly format back to when Vistagen Therapeutics, Inc. stock was issued.Fasedienol was also found to be well-tolerated with a favorable safety profile, according to Vistagen. The biotech’s stock skyrocketed 1,272% from market close Friday, rising from $1.68 per ...VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical headquartered in California that focuses on developing novel treatments for psychiatric and Central Nervous System [CNS] disorders.

October 14, 2021 08:00 ET | Source: VistaGen Therapeutics, Inc. Follow. Study Launches Phase 2A Clinical Program Designed to Explore PH94B’s Potential in Multiple Additional …Itruvone is an odorless synthetic investigational neuroactive pherine nasal spray designed with a novel, rapid-onset proposed mechanism of action (MOA) for the potential treatment of major depressive disorder (MDD). Itruvone’s proposed MOA is fundamentally differentiated from the MOA of all currently approved treatments for depression disorders.Stock analysis for Vistagen Therapeutics Inc (VTGN:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with potential to go beyond the current standard of care ...

VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety ... Itruvone is an odorless synthetic investigational neuroactive pherine nasal spray designed with a novel, rapid-onset proposed mechanism of action (MOA) for the potential treatment of major depressive disorder (MDD). Itruvone’s proposed MOA is fundamentally differentiated from the MOA of all currently approved treatments for depression disorders. Iovance Biotherapeutics Inc. -18.48%. $3.76B. VTGN | Complete Vistagen Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock …VistaGen Therapeutics (NASDAQ:VTGN) shares have completed a remarkable turnaround over the past 6 months. In October last year, the company was granted a 180-day extension to regain compliance ...

Make free calls online

Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting and with fewer side effects and safety concerns than those currently available ...

Nov 15, 2022 · Earnings Estimate Revisions for VistaGen Therapeutics, Inc. This company is expected to earn -$0.28 per share for the fiscal year ending March 2023, which represents a year-over-year change of -12%. About VistaGen. VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing new generation medicines for depression and other CNS disorders. VistaGen's lead CNS product candidate, AV-101, is an oral NMDA receptor GlyB antagonist in Phase 2 clinical development in the United States, initially as …VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical headquartered in California that focuses on developing novel treatments for psychiatric and Central Nervous System [CNS] disorders.In health-care professions, “therapeutic use of self” describes the ability of a caregiver to use his or her personality “consciously and in full awareness in an attempt to establi...VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other CNS disorders. VistaGen's lead CNS product candidate, AV-101, is in Phase 2 development, initially as a new generation oral antidepressant drug candidate …

About us. Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and …Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available for treatment of anxiety, depression and multiple CNS disorders. Vistagen’s pipeline includes six clinical-stage product candidates, including five investigational agents belonging ...19 Feb 2021 ... Shawn Singh has served as VistaGen's Chief Executive Officer since August 2009; he joined the Board of Directors in 2000. Mr. Singh has nearly ...The Investor Relations website contains information about Vistagen Therapeutics, Inc's business for stockholders, potential investors, and financial analysts.15 Dec 2022 ... Live stream the Vistagen Therapeutics, Inc (Nasdaq: VTGN) presentation from the December 15, 2022 KCSA Mental Health Virtual Investor ...

VistaGen Therapeutics stock is diving lower on poor results from a clinical trial. This saw a Phase 3 study of PH94B fail to meet its primary endpoint. This has heavy trading dragging the company ...

VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) March 31, March 31, 2022. 2021 ASSETS: Current assets:Track VistaGen Therapeutics Inc (VTGN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsVistaGen Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.22, expectations were $-0.31. VTGN isn't one of the 30 most popular stocks among hedge funds at the end of the third ...Shawn Singh has served as our Chief Executive Officer since August 2009; he joined our Board of Directors in 2000. Mr. Singh has nearly 30 years of experience working with private and public biotechnology, medical device, and pharmaceutical companies, a venture capital firm, and a profitable contract research and development organization (CRO ...VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen's drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all ...Vistagen boasts several clinical-stage neuroscience assets in its portfolio, spearheaded by its promising depression-focused drugs, itruvone, fasedienol, and …

Reagan library location

VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago.

The company develops therapeutics for treating anxiety, depression and other central nervous system (CNS) disorders. Business Areas: Small Molecules, ...With Vistagen Therapeutics stock trading at $4.41 per share, the total value of Vistagen Therapeutics stock (market capitalization) is $119.18M. Vistagen Therapeutics stock was originally listed at a price of $123.26 in May 11, 2016. If you had invested in Vistagen Therapeutics stock at $123.26, your return over the last 7 years …VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing new generation medicines for depression, SAD and other CNS diseases and disorders with high unmet need.The second half of 2022 was always going to be a high-stakes moment for VistaGen Therapeutics as it awaited data from two phase 3 trials for a social anxiety disorder nasal spray. And the stakes ...VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem with better outcomes for patients, caregivers, advocates and communities.Apr 25, 2021 · VistaGen Therapeutics (NASDAQ:VTGN) shares have completed a remarkable turnaround over the past 6 months. In October last year, the company was granted a 180-day extension to regain compliance ... Oct 14, 2021 · VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety ... VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem with better outcomes for patients, caregivers, advocates and communities.VistaGen Therapeutics (VistaGen) is a clinical-stage biopharmaceutical company that develops new-generation medicines for depression and neuropsychiatric disorders. The …Vistagen’s sixth investigational candidate is an oral prodrug with potential to modulate NMDA receptor activity. At Vistagen, we are passionate about delivering differentiated treatments that set new standards of care for people living with anxiety, depression, and other neurological disorders.SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet medical need, today announced positive results from a newly published …

Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for treatment of anxiety, depression and multiple CNS disorders. Vistagen’s pipeline includes six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), PH15 ...Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently …VistaGen Therapeutics. Phone: (650) 577-3606. Email: [email protected]. Company Profile VistaGen Therapeutics, Inc. Industry: Pharmaceuticals & Biotechnology Website: https://vistagen.com. PALISADE ...Instagram:https://instagram. total defense Apr 16, 2024 · The Investor Relations website contains information about Vistagen Therapeutics, Inc's business for stockholders, potential investors, and financial analysts. Vistagen Fiscal Year 2024 Third Quarter Corporate Update Conference Call. Feb 13, 2024 at 2:00 PM PST. Webcast. countdown to christmas Prior to joining Vistagen as Chief Commercial Officer, Ms. Cunningham served as Managing Partner of i 3 Strategy Partners, where she guided senior pharmaceutical and biotechnology executives in planning and executing successful portfolio strategies and brand launches. Her experience in the pharmaceutical industry includes numerous instrumental ... PH15 is an investigational pherine nasal spray with a novel, rapid-onset potential mechanism of action (MOA) that is fundamentally differentiated from the MOA of all currently approved treatments to improve cognitive impairment caused by mental fatigue and potentially other disorders. Vistagen believes PH15 has the potential to improve ... flights from dallas to honolulu Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other … anon chatting About VistaGen VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's drug candidates has a differentiated potential mechanism of action, has …Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, … abc kids Prior to joining Vistagen as Chief Commercial Officer, Ms. Cunningham served as Managing Partner of i 3 Strategy Partners, where she guided senior pharmaceutical and biotechnology executives in planning and executing successful portfolio strategies and brand launches. Her experience in the pharmaceutical industry includes numerous instrumental ... generator sitemap VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) March 31, March 31, 2022. 2021 ASSETS: Current assets: natural history museum dc Find the latest Vistagen Therapeutics, Inc. (VTGN) stock quote, history, news and other vital information to help you with your stock trading and investing.2 days ago · Vistagen Therapeutics, Inc is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Vistagen Therapeutics, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vistagen Therapeutics, Inc or its management. sfo to japan flight At Vistagen, corporate responsibility is fundamental to our mission and we are committed to holding ourselves to high ethical standards. Beyond our quest to pioneer new neuroscience therapies, we strive to create a positive impact for our employees, our local communities, our patients, our stockholders, the healthcare ecosystem, and society. sound to text converter For Individuals and Support Networks. Vistagen’s core goal is to radically improve mental health worldwide. With that clear vision always in mind, and knowing that no mental health challenge is routine or resolvable with a “one-size-fits-all” solution, we are committed to advancing development of innovative drug candidates with the ... rogers place VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety ...About VistaGen VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three drug candidates has a differentiated potential mechanism of action, … azure security center VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental …6 VistaGen Therapeutics jobs. Apply to the latest jobs near you. Learn about salary, employee reviews, interviews, benefits, and work-life balance.VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2022 2022 (unaudited) ASSETS: Current assets: Cash and cash equivalents $ 51,986,400 $ 68,135,300 Prepaid expenses and other current assets 2,890,300 2,745,800